erlotinib has been researched along with Triple Negative Breast Neoplasms in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jiang, Y; Ouyang, L; Sun, D; Wang, J; Yang, S; Yao, D; Yu, Y; Zhang, J; Zhao, Y; Zhou, Y; Zhu, L | 1 |
1 other study(ies) available for erlotinib and Triple Negative Breast Neoplasms
| Article | Year |
|---|---|
Design, synthesis and structure-activity relationship studies of a focused library of pyrimidine moiety with anti-proliferative and anti-metastasis activities in triple negative breast cancer.
Topics: Antineoplastic Agents; Apoptosis; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Molecular Structure; Pyrimidines; Structure-Activity Relationship; Triple Negative Breast Neoplasms; Tumor Cells, Cultured | 2017 |